GPRC5D and plasma cell myeloma: In our case report, we successfully treated a patient with relapsed and refractory nonsecretory multiple myeloma, who had multiple high‐risk factors, including extramedullary disease and TP53 deletion, using GPRC5D‐targeted CAR‐T cells.